Risk factors of hepatitis during Anti-tuberculous treatment and implications of hepatitis virus load

Journal of Infection

Volumn 62, Issue 6, 2011, Pages 448-455

  Wang, Jann Yuan ^a   Liu, Chen Hua ^a   Hu, Fu Chang ^a   Chang, Hsiu Ching ^a   Liu, Jia Luen ^a   Chen, Jong Min ^a   Yu, Chong Jen ^a   Lee, Li Na ^a   Kao, Jia Horng ^a   Yang, Pan Chyr ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Anti tuberculous treatment; Gender; Hepatitis; NAT2; Viral hepatitis

Indexed keywords

ARYLAMINE ACETYLTRANSFERASE; CYTOCHROME P450 2E1; TUBERCULOSTATIC AGENT;

ABDOMINAL DISCOMFORT; ACETYLATOR PHENOTYPE; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANOREXIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHRONIC KIDNEY DISEASE; COMORBIDITY; CONTROLLED STUDY; CYTOCHROME P450 2E1 GENE; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG FATALITY; DRUG INDUCED DISEASE; FEMALE; FOLLOW UP; GENETIC SUSCEPTIBILITY; GENOTYPE; HEPATITIS; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HYPERTRANSAMINASEMIA; INFECTION RISK; LIVER FAILURE; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALAISE; MALE; N ACETYLTRANSFERASE 2 GENE; NAUSEA; NONHUMAN; PREDICTION; PROSPECTIVE STUDY; RISK FACTOR; SEX DIFFERENCE; SIDE EFFECT; VIRUS GENE; VIRUS LOAD; VOMITING;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTITUBERCULAR AGENTS; FEMALE; HEPATITIS B; HEPATITIS C; HUMANS; MALE; MIDDLE AGED; PREVALENCE; PROSPECTIVE STUDIES; RISK FACTORS; TRANSAMINASES; TUBERCULOSIS; VIRAL LOAD; YOUNG ADULT;

EID: 79958795992     PISSN: 01634453     EISSN: 15322742     Source Type: Journal    
DOI: 10.1016/j.jinf.2011.04.005     Document Type: Article

References (35)

1. CDC, and infectious diseases Society of America. Treatment of tuberculosis. MMWR Recomm Rep 2003, 52(RR-11):1-77. American Thoracic Society.
2. Wang J.Y., Lee L.N., Yu C.J., Chien Y.J., Yang P.C. Factors influencing time to smear conversion in patients with smear-positive pulmonary tuberculosis. Respirology 2009, 14(7):1012-1019.
3. Huang Y.S., Chern H.D., Su W.J., Wu J.C., Lai S.L., Yang S.Y., et al. Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatitis. Hepatology 2002, 35(4):883-889.
4. Possuelo L.G., Castelan J.A., de Brito T.C., Ribeiro A.W., Cafrune P.I., Picon P.D., et al. Association of slow N-acetyltransferase 2 profile and anti-TB drug-induced hepatotoxicity in patients from Southern Brazil. Eur J Clin Pharmacol 2008, 64(7):673-681.
5. Shen C., Meng Q., Zhang G., Hu W. Rifampicin exacerbates isoniazid-induced toxicity in human but not in rat hepatocytes in tissue-like cultures. Br J Pharmacol 2008, 153(4):784-791.
6. Huang Y.S., Su W.J., Huang Y.H., Chen C.Y., Chang F.Y., Lin H.C., et al. Genetic polymorphisms of manganese superoxide dismutase, NAD(P)H:quinone oxidoreductase, glutathione S-transferase M1 and T1, and the susceptibility to drug-induced liver injury. J Hepatol 2007, 47(1):128-134.
7. Pande J.N., Singh S.P., Khilnani G.C., Khilnani S., Tandon R.K. Risk factors for hepatotoxicity from antituberculosis drugs: a case-control study. Thorax 1996, 51(2):132-136.
8. Teleman M.D., Chee C.B., Earnest A., Wang Y.T. Hepatotoxicity of tuberculosis chemotherapy under general programme conditions in Singapore. Int J Tuberc Lung Dis 2002, 6(8):699-705.
9. Sharma S.K., Balamurugan A., Saha P.K., Pandey R.M., Mehra N.K. Evaluation of clinical and immunogenetic risk factors for the development of hepatotoxicity during antituberculosis treatment. Am J Respir Crit Care Med 2002, 166(7):916-919.
10. Fernandez-Villar A., Sopena B., Fernandez-Villar J., Vazquez-Gallardo R., Ulloa F., Leiro V., et al. The influence of risk factors on the severity of anti-tuberculosis drug-induced hepatotoxicity. Int J Tuberc Lung Dis 2004, 8(12):1499-1505.
11. Shakya R., Rao B.S., Shrestha B. Incidence of hepatotoxicity due to antitubercular medicines and assessment of risk factors. Ann Pharmacother 2004, 38(6):1074-1079.
12. Lee B.H., Koh W.J., Choi M.S., Suh G.Y., Chung M.P., Kim H., et al. Inactive hepatitis B surface antigen carrier state and hepatotoxicity during antituberculosis chemotherapy. Chest 2005, 127(4):1304-1311.
13. Wong W.M., Wu P.C., Yuen M.F., Cheng C.C., Yew W.W., Wong P.C., et al. Antituberculosis drug-related liver dysfunction in chronic hepatitis B infection. Hepatology 2000, 31(1):201-206.
14. Kwon Y.S., Koh W.J., Suh G.Y., Chung M.P., Kim H., Kwon O.J. Hepatitis C virus infection and hepatotoxicity during antituberculosis chemotherapy. Chest 2007, 131(3):803-808.
15. Ungo J.R., Jones D., Ashkin D., Hollender E.S., Bernstein D., Albanese A.P., et al. Antituberculosis drug-induced hepatotoxicity. The role of hepatitis C virus and the human immunodeficiency virus. Am J Respir Crit Care Med 1998, 157(6 Pt 1):1871-1876.
16. Ozick L.A., Jacob L., Comer G.M., Lee T.P., Ben-Zvi J., Donelson S.S., et al. Hepatotoxicity from isoniazid and rifampin in inner-city AIDS patients. Am J Gastroenterol 1995, 90(11):1978-1980.
17. Chen C.J., Yang H.I. Natural history of chronic hepatitis B REVEALed. J Gastroenterol Hepatol 2011.
18. Lee M.H., Yang H.I., Jen C.L., Lu S.N., Yeh S.H., Liu C.J., et al. Community and personal risk factors for hepatitis C virus infection: a survey of 23 820 residents in Taiwan in 1991-2. Gut 2010.
19. Nolan C.M., Goldberg S.V., Buskin S.E. Hepatotoxicity associated with isoniazid preventive therapy: a 7-year survey from a public health tuberculosis clinic. JAMA 1999, 281(11):1014-1018.
20. Chen C.J., Yang H.I., Su J., Jen C.L., You S.L., Lu S.N., et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006, 295(1):65-73.
21. Jensen D.M., Morgan T.R., Marcellin P., Pockros P.J., Reddy K.R., Hadziyannis S.J., et al. Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy. Hepatology 2006, 43(5):954-960.
22. Levey A.S., Bosch J.P., Lewis J.B., Greene T., Rogers N., Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999, 130(6):461-470.
23. Hein DW, Grant DM, Slim E, Minchin RF, Boukouvala S. Human NAT2 alleles (Haplotypes). Arylamine N-acetyltransferase gene Nomenclature Committee; 2008 [updated May 27]; Available from: http://louisville.edu/medschool/pharmacology/Human.NAT2.pdf.
24. Sarma G.R., Immanuel C., Kailasam S., Narayana A.S., Venkatesan P. Rifampin-induced release of hydrazine from isoniazid. A possible cause of hepatitis during treatment of tuberculosis with regimens containing isoniazid and rifampin. Am Rev Respir Dis 1986, 133(6):1072-1075.
25. Tostmann A., Boeree M.J., Peters W.H., Roelofs H.M., Aarnoutse R.E., van der Ven A.J., et al. Isoniazid and its toxic metabolite hydrazine induce in vitro pyrazinamide toxicity. Int J Antimicrob Agents 2008, 31(6):577-580.
26. Schenker S., Martin R.R., Hoyumpa A.M. Antecedent liver disease and drug toxicity. J Hepatol 1999, 31(6):1098-1105.
27. Hunt C.M., Westerkam W.R., Stave G.M. Effect of age and gender on the activity of human hepatic CYP3A. Biochem Pharmacol 1992, 44(2):275-283.
28. Poynard T., Ratziu V., Charlotte F., Goodman Z., McHutchison J., Albrecht J. Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis c. J Hepatol 2001, 34(5):730-739.
29. Shimizu I., Kohno N., Tamaki K., Shono M., Huang H.W., He J.H., et al. Female hepatology: favorable role of estrogen in chronic liver disease with hepatitis B virus infection. World J Gastroenterol 2007, 13(32):4295-4305.
30. Kim Y.G., Shin J.G., Shin S.G., Jang I.J., Kim S., Lee J.S., et al. Decreased acetylation of isoniazid in chronic renal failure. Clin Pharmacol Ther 1993, 54(6):612-620.
31. Cash J.M., Zawada E.T. Isoniazid overdose. Successful treatment with pyridoxine and hemodialysis. West J Med 1991, 155(6):644-646.
32. Malone R.S., Fish D.N., Spiegel D.M., Childs J.M., Peloquin C.A. The effect of hemodialysis on isoniazid, rifampin, pyrazinamide, and ethambutol. Am J Respir Crit Care Med 1999, 159(5 Pt 1):1580-1584.
33. Fabrizi F., Lunghi G., Alongi G., Aucella F., Barbisoni F., Bisegna S., et al. Kinetics of hepatitis B virus load and haemodialysis: a prospective study. J Viral Hepat 2008, 15(12):917-921.
34. Fabrizi F., Messa P., Martin P. Impact of hemodialysis therapy on hepatitis C virus infection: a deeper insight. Int J Artif Organs 2009, 32(1):1-11.
35. Sharma S.K., Singla R., Sarda P., Mohan A., Makharia G., Jayaswal A., et al. Safety of 3 different reintroduction regimens of antituberculosis drugs after development of antituberculosis treatment-induced hepatotoxicity. Clin Infect Dis 2010, 50(6):833-839.